Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction: Bispecific antibodies that engage immu...

Full description

Bibliographic Details
Main Authors: Pan H, Liu J, Deng W, Xing J, Li Q, Wang Z
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:International Journal of Nanomedicine
Subjects:
Fab
nanobody
PEGylation
bispecific antibody
half-life
CEA
Online Access:https://www.dovepress.com/site-specific-pegylation-of-an-anti-ceacd3-bispecific-antibody-improve-peer-reviewed-article-IJN

Internet

https://www.dovepress.com/site-specific-pegylation-of-an-anti-ceacd3-bispecific-antibody-improve-peer-reviewed-article-IJN

Similar Items